These clinical stage fluorescent molecular contrast agents can target cancer cells via surface receptors such as the epidermal growth factor receptor (EGFR), prostate specific membrane antigen (PSMA), and cathepsins which would provide the ability to target many different types of cancers [31, 56–58]. Here, FOLH1 is linked to cancer.